Section Navigation

Celsion announces TARDOX study combining ThermoDox and focused ultrasound to tackle cancers

Celsion Corporation has launched a clinical trial, supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), to study the effectiveness of combining cancer drug ThermoDox with focused ultrasound to treat a range of tumours, including liver cancer.

For the full story on Oxford Biomedical Research Centre website

Copyright 2017 © Oxford Academic Health Science Centre